When did HAEMONETICS CORP/MASS (HAE) report earnings last quarter?
HAEMONETICS CORP/MASS (HAE) last reported earnings on 2/5/2026.
HAEMONETICS CORP/MASS (HAE) Earnings History & Surprises
NYSE:HAE • US4050241003
Current stock price
59.92 USD
+0.43 (+0.72%)
At close:
59.92 USD
0 (0%)
After Hours:
HAE Earnings overview
Past quarterly earnings results for HAEMONETICS CORP/MASS (HAE), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- May 6, 2026
- Period
- Q4 / 2026
- EPS Estimate
- $1.28
- Revenue Estimate
- 340.41M
Last Reported
Most Recent- Release Date
- Feb 5, 2026
- Period
- Q3 / 2026
- EPS Reported
- $1.31
- EPS Surprise
- 3.75%
- Revenue Surprise
- 1.21%
Beat Rate
Last 8 Quarters 69%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q3 2026 | 1.31 | 1.26 | 3.75% | 10.08% | 338.967M | 334.93M | 1.21% | -2.75% |
| Q2 2026 | 1.27 | 1.12 | 13.26% | 13.39% | 327.315M | 314.51M | 4.07% | -5.27% |
| Q1 2026 | 1.10 | 1.03 | 7.20% | 7.84% | 321.394M | 307.42M | 4.55% | -4.40% |
| Q4 2025 | 1.24 | 1.23 | 0.62% | 37.78% | 330.599M | 332.68M | -0.63% | -3.70% |
| Q3 2025 | 1.19 | 1.18 | 0.69% | 14.42% | 348.542M | 356.46M | -2.22% | 3.66% |
| Q2 2025 | 1.12 | 1.08 | 3.35% | 13.13% | 345.511M | 346.07M | -0.16% | 8.59% |
| Q1 2025 | 1.02 | 1.02 | 0.44% | -2.86% | 336.172M | 338.73M | -0.76% | 7.98% |
| Q4 2024 | 0.90 | 0.90 | -0.02% | 16.88% | 343.29M | 332.4M | 3.28% | 12.77% |
| Q3 2024 | 1.04 | 0.95 | 9.38% | 22.35% | 336.25M | 323.5M | 3.94% | 10.14% |
| Q2 2024 | 0.99 | 0.90 | 10.37% | 19.28% | 318.183M | 316.25M | 0.61% | 6.95% |
| Q1 2024 | 1.05 | 0.74 | 42.31% | 81.03% | 311.332M | 295.62M | 5.31% | 19.06% |
| Q4 2023 | 0.77 | 0.71 | 8.16% | 18.46% | 304.416M | 292.54M | 4.06% | 14.87% |
| Q3 2023 | 0.85 | 0.81 | 4.81% | 1.19% | 305.3M | 303.47M | 0.60% | 17.51% |
| Q2 2023 | 0.83 | 0.68 | 21.95% | 38.33% | 297.5M | 271.91M | 9.41% | 24.01% |
| Q1 2023 | 0.58 | 0.52 | 12.50% | 16.00% | 261.5M | 251.49M | 3.98% | 14.44% |
| Q4 2022 | 0.65 | 0.61 | 7.16% | 41.30% | 265M | 259.03M | 2.30% | 17.78% |
| Q3 2022 | 0.84 | 0.74 | 13.25% | 3.70% | 259.8M | 269.41M | -3.57% | 8.07% |
| Q2 2022 | 0.60 | 0.61 | -1.99% | -3.23% | 239.9M | 243.82M | -1.61% | 14.51% |
| Q1 2022 | 0.50 | 0.45 | 10.01% | 8.70% | 228.5M | 221.55M | 3.14% | 16.82% |
| Q4 2021 | 0.46 | 0.68 | -32.20% | -33.33% | 225M | 225.21M | -0.09% | -5.66% |
| Q3 2021 | 0.81 | 0.66 | 22.57% | -13.83% | 240.4M | 226.53M | 6.12% | -7.18% |
| Q2 2021 | 0.62 | 0.51 | 21.42% | -28.74% | 209.5M | 209.73M | -0.11% | -17.06% |
| Q1 2021 | 0.46 | 0.42 | 10.09% | -43.21% | 195.6M | 200.26M | -2.33% | -17.99% |
| Q4 2020 | 0.69 | 0.74 | -6.36% | - | 238.5M | 249M | -4.22% | - |
| Q3 2020 | 0.94 | 0.77 | 22.83% | - | 259M | 257.96M | 0.40% | - |
| Q2 2020 | 0.87 | 0.70 | 23.99% | - | 252.6M | 252.27M | 0.13% | - |
| Q1 2020 | 0.81 | 0.64 | 26.44% | - | 238.5M | 240.09M | -0.66% | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
4
Average EPS beat (4)
6.21%
Max EPS beat (4)
13.26%
Min EPS beat (4)
0.62%
Revenue beat statistics
Revenue beat (4)
3
Average Revenue beat (4)
2.30%
Max Revenue beat (4)
4.55%
Min Revenue beat (4)
-0.63%
Analysis
In the last 4 quarters, HAE has consistently beaten EPS estimates in all releases
HAE has beaten revenue estimates in 3 out of the last 4 releases
In the last 4 quarters, HAE has beaten the EPS estimates by 6.2% on average.
In the last 4 quarters, HAE has beaten the revenue estimates by 2.3% on average.
Related analysis
HAEMONETICS CORP/MASS / HAE Earnings FAQ
Can you provide information on whether HAEMONETICS CORP/MASS beat earnings estimates in the last quarter?
HAEMONETICS CORP/MASS (HAE) beat EPS estimates and beat revenue estimates in the most recent quarter.
What percentage of the time does HAE stock beat earnings estimates?
In the last 4 quarters, HAEMONETICS CORP/MASS (HAE) has beaten EPS estimates in 4 out of 4 releases.